These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 7700752)

  • 1. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen.
    Bewley KM; Schwab JG; Ballanco GA; Daum RS
    Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
    Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C
    P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?
    Scheifele D; Barreto L; Meekison W; Guasparini R; Friesen B
    CMAJ; 1993 Oct; 149(8):1105-12. PubMed ID: 8221449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile.
    Hoppenbrouwers K; Lagos R; Swennen B; Ethevenaux C; Knops J; Levine MM; Desmyter J
    Vaccine; 1998; 16(9-10):921-7. PubMed ID: 9682338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
    Eskola J; Olander RM; Hovi T; Litmanen L; Peltola S; Käyhty H
    Lancet; 1996 Dec 21-28; 348(9043):1688-92. PubMed ID: 8973430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered.
    Daum RS; Zenko CE; Given GZ; Ballanco GA; Parikh H; Germino K
    J Infect Dis; 2001 Nov; 184(10):1293-9. PubMed ID: 11679918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K
    Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine.
    Kurikka S; Käyhty H; Peltola H; Saarinen L; Eskola J; Mäkelä PH
    Pediatrics; 1995 Jun; 95(6):815-22. PubMed ID: 7761204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
    Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.